Eurasian Common Medicines Market Gets Off The Ground
Executive SummaryThe new regulatory framework in the Eurasian Economic Union is now in place and the first drug approval applications have been filed under the mutual recognition system. Applications are expected to rise significantly in 2019 once IT systems are fully in place and more experience has been gained.
You may also be interested in...
Pharmaceutical and medical product companies operating in countries of the Eurasian Economic Union (EAEU) will soon be facing a new set of regulations that among other things are intended to establish a single EAEU market with free movement of medicines and medical goods, introduce a new decentralized drug approvals procedure, and help bring down pharmaceutical prices through greater competition.
Regulators have pulled out all the stops in their efforts to get the Ebola vaccine to the marketing authorization stage in Africa.
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.